Morning Briefing
Summaries of health policy coverage from major news organizations
'Skinny Labeling' Case To Be Reheard
In a surprising move, a federal appeals court panel may revisit a controversial decision that has raised concerns about the ability of generic drug makers to supply Americans with lower-cost alternatives to pricey brand-name medicines. (Silverman, 2/9)
In other pharmaceutical industry news 鈥
KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling 鈥渁ttacks鈥 commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a mid-stage clinical trial. (Feuerstein, 2/9)
On Monday, Editas Medicines announced that veteran biopharma executive James 鈥淛im鈥 Mullen was expanding his role with the gene-editing biotech, taking over as the new CEO while continuing as the company鈥檚 chairman 鈥 a role he鈥檚 held since March 2018. Mullen replaces Cynthia Collins, who became Editas鈥 CEO in August 2019. (Feuerstein, 2/9)
